Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IMVT | US
-0.33
-1.14%
Healthcare
Biotechnology
30/06/2024
24/04/2026
28.58
28.96
29.18
28.29
Immunovant Inc. a clinical-stage biopharmaceutical company develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York New York. Immunovant Inc. is a subsidiary of Roivant Sciences Ltd.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
High Short-term Volatility
Midcap (2B - 10B USD)
High Short percentage (> 15%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
59.4%1 month
54.0%3 months
49.9%6 months
53.2%-
-
7.86
0.00
0.00
-14.12
-
-
-298.26M
4.18B
4.18B
-
-
-
-
-64.55
11.04
19.76
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
5.73
Range1M
6.71
Range3M
7.30
Rel. volume
0.89
Price X volume
37.75M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Terns Pharmaceuticals Inc. | TERN | Biotechnology | 52.89 | 4.47B | 0.11% | n/a | 0.11% |
| Legend Biotech Corp | LEGN | Biotechnology | 23.9 | 4.40B | -0.38% | n/a | 29.24% |
| Mirum Pharmaceuticals Inc | MIRM | Biotechnology | 91.49 | 4.36B | -0.50% | n/a | 138.24% |
| Amicus Therapeutics Inc | FOLD | Biotechnology | 14.49 | 4.30B | 0.21% | n/a | 335.08% |
| Ligand Pharmaceuticals Incorporated | LGND | Biotechnology | 231.27 | 4.23B | 1.22% | 45.66 | 0.98% |
| Scholar Rock Holding Corporation | SRRK | Biotechnology | 46.48 | 4.20B | -2.11% | n/a | 50.92% |
| Xenon Pharmaceuticals Inc | XENE | Biotechnology | 55.24 | 4.19B | -0.31% | n/a | 1.19% |
| CRISPR Therapeutics AG | CRSP | Biotechnology | 48.785 | 4.15B | -11.59% | n/a | 11.68% |
| Fluent Inc | COGT | Biotechnology | 36.81 | 4.03B | 1.85% | n/a | 4.87% |
| Amneal Pharmaceuticals Inc | AMRX | Drug Manufacturers-Specialty & Generic | 12.52 | 3.88B | -1.03% | n/a | -4742.26% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Thor Industries Inc | THO | Recreational Vehicles | 79 | 4.18B | 0.24% | 23.44 | 27.88% |
| VeriFone Systems Inc | PAY | Building Products & Equipment | 27.25 | 3.39B | 0.96% | 102.46 | 2.10% |
| Polaris Industries Inc | PII | Recreational Vehicles | 60.04 | 3.35B | 1.06% | 14.48 | 170.51% |
| LCI Industries | LCII | Recreational Vehicles | 120.01 | 3.06B | -0.45% | 25.82 | 77.66% |
| Harley-Davidson Inc | HOG | Recreational Vehicles | 23.11 | 3.04B | -1.15% | 7.33 | 218.58% |
| Pitney Bowes Inc | PBI | Building Products & Equipment | 15.58 | 2.80B | 1.37% | n/a | -571.93% |
| HNI Corporation | HNI | Building Products & Equipment | 37.7 | 1.78B | 1.32% | 22.12 | 76.47% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 14.6 | 1.46B | 3.03% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 39.11 | 1.23B | -1.21% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 32.87 | 951.75M | 0.70% | 22.53 | 56.33% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -14.12 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 7.86 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 49.92 | 72.80 | Lower Risk |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 4.18B | 3.66B | Par |